康惠制药
(603139)
| 流通市值：15.64亿 | | | 总市值：15.64亿 |
| 流通股本：9988.00万 | | | 总股本：9988.00万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 404,545,531.96 | 265,668,337.76 | 127,367,068.27 | 672,960,241.75 |
| 营业收入 | 404,545,531.96 | 265,668,337.76 | 127,367,068.27 | 672,960,241.75 |
| 二、营业总成本 | 455,454,003.35 | 288,768,212.05 | 133,377,175.4 | 685,241,049.88 |
| 营业成本 | 274,500,711.5 | 178,764,263.19 | 85,992,349.81 | 483,748,383.27 |
| 税金及附加 | 9,261,537.52 | 6,758,566.88 | 3,505,313.33 | 5,304,781.55 |
| 销售费用 | 105,421,513.96 | 60,301,862.14 | 20,621,173.43 | 121,683,999.74 |
| 管理费用 | 39,052,974.64 | 24,919,425.53 | 14,286,017.41 | 45,230,599.63 |
| 研发费用 | 4,697,380.27 | 3,386,639.75 | 1,824,618.48 | 10,980,089.51 |
| 财务费用 | 22,519,885.46 | 14,637,454.56 | 7,147,702.94 | 18,293,196.18 |
| 其中:利息费用 | 25,377,613.47 | 16,065,406.22 | 7,820,156.66 | 23,461,102.82 |
| 其中:利息收入 | 2,466,449.88 | 1,519,262 | 781,968.27 | 5,324,465.38 |
| 加:公允价值变动收益 | 2,061,918 | 1,261,918 | - | -101,078.53 |
| 加:投资收益 | 2,304,092.47 | 11,507,042.46 | 576,639.86 | -28,643,865.66 |
| 资产处置收益 | -34,282.31 | -34,282.31 | -3,653.83 | 95,208.27 |
| 资产减值损失(新) | -766,663.32 | 927.91 | -37,055.92 | -20,744,576.31 |
| 信用减值损失(新) | -3,896,391.46 | -3,076,546.94 | 1,560,111.06 | -3,828,067.83 |
| 其他收益 | 5,260,048.68 | 4,091,129.65 | 2,689,010.39 | 3,700,631.69 |
| 营业利润平衡项目 | 0 | 0 | 0.01 | 0 |
| 四、营业利润 | -45,979,749.33 | -9,349,685.52 | -1,225,055.56 | -61,802,556.5 |
| 加:营业外收入 | 441,174.67 | 145,569.54 | 73,455.14 | 4,839,652.13 |
| 减:营业外支出 | 715,605.86 | 677,679.08 | 437,091.27 | 980,406.89 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -46,254,180.52 | -9,881,795.06 | -1,588,691.69 | -57,943,311.26 |
| 减:所得税费用 | 1,528,033.33 | 7,226,599.16 | 894,298.91 | -7,168,114.89 |
| 六、净利润 | -47,782,213.85 | -17,108,394.22 | -2,482,990.6 | -50,775,196.37 |
| 持续经营净利润 | -47,782,213.85 | -17,108,394.22 | -2,482,990.6 | -50,775,196.37 |
| 归属于母公司股东的净利润 | -38,288,437.47 | -8,701,972.53 | 1,086,299.01 | -26,158,640.74 |
| 少数股东损益 | -9,493,776.38 | -8,406,421.69 | -3,569,289.61 | -24,616,555.63 |
| (一)基本每股收益 | -0.38 | -0.09 | 0.01 | -0.26 |
| (二)稀释每股收益 | -0.38 | -0.09 | 0.01 | -0.26 |
| 八、其他综合收益 | - | - | - | 1,890,974.41 |
| 归属于母公司股东的其他综合收益 | - | - | - | 1,890,974.41 |
| 九、综合收益总额 | -47,782,213.85 | -17,108,394.22 | -2,482,990.6 | -48,884,221.96 |
| 归属于母公司股东的综合收益总额 | -38,288,437.47 | -8,701,972.53 | 1,086,299.01 | -24,267,666.33 |
| 归属于少数股东的综合收益总额 | -9,493,776.38 | -8,406,421.69 | -3,569,289.61 | -24,616,555.63 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |